Axillary Reverse Mapping (ARM) in Breast Cancer Surgery to Prevent Lymphedema. (ARMtrial)
NCT03333226 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300
Last updated 2018-01-23
Summary
Breast cancer related lymphedema (BCRL) is a debilitating and distressing condition affecting approximately one out of five breast cancer survivors. BCRL is a chronic swelling of the upper arm following axillary lymph nodes dissection, and it is associated to a significant functional, psychological and social morbidity, with an heavy impact on life quality. Several studies reported BCRL incidence between 6.7% and 62.5% for different population cohorts. Randomized clinical trials (RCTs) reported that sentinel lymph node biopsy (SLNB) when compared with axillary lymph node dissection (ALND) leads to a significant reduction in postoperative complications. However, the advent of SLNB does not solve the problem of BCRL with a concrete chance to develop a lymphedema after single SLNB around 7%. Health care cost of BCRL rehabilitative treatment is not available in literature yet. Few studies considered incidence, risk factors and treatment costs of BCRL among working-age women after breast cancer treatment, reporting that BCRL population had significantly higher rehabilitative medical costs ($14,877 to $23,167) with twice as much risk to develop BCRL complications, such as lymphangitis or cellulitis when compared to "BCRL free" population (OR = 2.02, P = .009).
Axillary reverse mapping (ARM) procedure claims to map and preserve arm lymphatic drainage during ALND and/or during SLNB, reducing BCRL development. ARM is developed as result of assumption that arm's lymphatic pathway is not involved by metastatic tumor cells of the primary breast cancer. However, when the arm lymph node correspond to the SLN it should be removed for correct tumor staging, thus a lymphatic drainage disruption onset will be expected with BCRL risk increase.
During the ARM procedure, a fluorescence imaging technique (photodynamic procedure) is useful for detecting lymphatic drainage of the upper limb and it allows in differentiating the fluorescent ARM node from the SLN identified by the radioguided technique (99mTC-Nanocoll).
Conditions
- Breast Cancer Lymphedema
Interventions
- PROCEDURE
-
Axillary Reverse Mapping (ARM)
ARM lymph node preservation versus removal
Sponsors & Collaborators
-
University Hospital of Ferrara
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-01-17
- Primary Completion
- 2020-12-31
- Completion
- 2020-12-31
Countries
- Italy
Study Locations
More Related Trials
-
Pre-existing Factors, Early Detection and Early Treatment of Breast Cancer Related Lymphedema
NCT03210311 ·Status: COMPLETED ·Phase: NA
-
Can ILR Reduce the Risk of Arm Lymphedema?
NCT05742945 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Axillary Reverse Mapping
NCT00572481 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Axillary Reverse Mapping for Invasive Carcinoma of the Breast
NCT00645541 ·Status: COMPLETED ·Phase: PHASE1
-
Axillary Reverse Mapping Using Methylene Blue Subcutaneous Injection Can Identify Arm Lymph Nodes and Vessels, Measuring Arm Size for Lymphedema, Histopathological Examination of Arm Lymph Nodes Included With Axillary Lymph Node Dissection
NCT04137744 ·Status: COMPLETED ·Phase: NA
-
Nomogram to Predict Breast Cancer Related Lymphedema
NCT04665882 ·Status: RECRUITING ·Phase: NA
-
Reduction of Arm Volume and Improvement in Lymphedema Via Surgery
NCT06606145 ·Status: COMPLETED ·Phase: NA
-
Axillary Reverse Mapping for Breast Carcinomas
NCT01146158 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Axillary Lymphadenectomy Without Drainage for Breast Cancer
NCT01267552 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
ILR to Prevent BRCL_MCC 23608
NCT07127003 ·Status: RECRUITING ·Phase: NA
-
Predictors of Lymphedema Following Breast Cancer Surgery
NCT00202046 ·Status: COMPLETED
-
Identification and Preservation of Arm Lymphatics
NCT04446494 ·Status: UNKNOWN ·Phase: NA
-
To Assess the Efficacy of the LYMPHA in the Prevention of Lymphedema Following Axillary Dissection for Breast Cancer
NCT04328610 ·Status: UNKNOWN ·Phase: NA
-
Study of the Change of Breast Cancer Patients' Upper Limb Lymphatic Drainage Pathway After Operation
NCT02691624 ·Status: UNKNOWN
-
Selective Axillary Lymph Node Dissection Vs Complete Axillary Dissection: A Randomised Clinical Trial to Assess the Prevention of Lymphedema in Breast Cancer Treatment
NCT03083314 ·Status: COMPLETED ·Phase: NA
-
Manual Lymphatic Drainage Versus Standard Treatment for the Prevention of Breast Cancer-related Lymphoedema in Patients Who Undergo Axillary Node Clearance
NCT04582565 ·Status: COMPLETED ·Phase: NA
-
Axillary Reverse Mapping (ARM) Technique
NCT03109522 ·Status: UNKNOWN ·Phase: NA
-
Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Stage 0-2 Patients.
NCT01276054 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
NCT06144164 ·Status: RECRUITING ·Phase: PHASE3
-
Lymphedema Surveillance Study
NCT02743858 ·Status: RECRUITING
-
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
NCT07140172 ·Status: RECRUITING ·Phase: NA
-
Does Immediate Lymphatic Reconstruction Decrease the Risk of Lymphedema After Axillary Lymph Node Dissection
NCT04241341 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Selective Image Guided Resection of Pathologically Documented Axillary Lymph Node Metastases
NCT03281720 ·Status: COMPLETED ·Phase: NA
-
Lymphedema Prevention in Breast Cancer
NCT04112966 ·Status: COMPLETED ·Phase: NA
-
Axillary Lymph Node Preservation Surgery in Reducing Lymphedema in Patients With Breast Cancer
NCT00932035 ·Status: TERMINATED ·Phase: PHASE1/PHASE2